Quarterly report pursuant to Section 13 or 15(d)

Goodwill and In-process R&D

v3.20.1
Goodwill and In-process R&D
3 Months Ended
Mar. 31, 2020
Goodwill and In-process R&D  
Goodwill and In-process R&D

7. Goodwill and In-Process R&D

Goodwill of $2.2 million and in-process R&D of $5.9 million were recorded in connection with the acquisition of Pelican, as described in Note 2. The Company performs an annual impairment test at the reporting unit level in the second quarter of each fiscal year. However, during the year ended December 31, 2019, the Company experienced a sustained decline in the quoted market price of the Company’s common stock and as a result the Company determined that as of December 31, 2019 it was more likely than not that the carrying value of these acquired intangibles exceeded their estimated fair value.  Accordingly, the Company performed an interim impairment analysis as of that date using the income approach. This analysis required significant judgments, including primarily the estimation of future development costs, the probability of success in various phases of its development programs, potential post-launch cash flows and a risk-adjusted weighted average cost of capital. Pursuant to ASU 2017‑04, the Company recorded a goodwill impairment charge for the excess of the reporting unit’s carrying value over its fair value.  During the year ended December 31, 2019, goodwill with a total carrying value of $2.2 million was written down to its estimated fair value of $1.5 million and an impairment charge of $0.7 million was recorded.  No impairment was recorded during the quarter ended March 31, 2020.